Archimedes Pharma

archimedespharma.com

Archimedes Pharma is an international specialty pharmaceutical company providing novel and advanced treatments to address unmet needs for people living with serious or life-threatening chronic and debilitating illnesses. Marketing a diverse portfolio of specialty products focused on the oncology, pain, and critical care sectors, Archimedes Pharma has operations in Europe.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Business Insights, PHARMA TECH

CONTINUUS PHARMACEUTICALS ADOPTS DIGITAL VALIDATION

CONTINUUS Pharmaceuticals | March 15, 2023

news image

On March 14, 2023, ValGenesis, Inc., a leading enterprise validation lifecycle management solutions provider, announced that CONTINUUS Pharmaceuticals has successfully implemented the ValGenesis Validation Lifecycle Management System (VLMS) for efficient management of validation processes across the company in a 100% digital format. CONTINUUS Pharmaceuticals is a rapidly growing small business specializing in end-to-end integrated continuous manufacturing (ICM) of pharmaceutical...

Read More

Business Insights, PHARMACY MARKET

XERIS PHARMACEUTICALS ANNOUNCES USFDA APPROVAL OF RECORLEV

Xeris Pharmaceuticals, Inc. | January 31, 2023

news image

On January 30, 2023, Xeris Biopharma Holdings, Inc., a leading biopharmaceutical company, announced that the Food and Drug Administration (FDA) granted orphan-drug exclusivity (ODE) to its subsidiary Xeris Pharmaceuticals, Inc. for Recorlev® (levoketoconazole) a cortisol synthesis inhibitor for the treatment of endogenous Cushing's syndrome in adult patients for whom surgery is not viable or has not been effective. levoketoconazole (Recorlev) being the first FDA-approved...

Read More

Pharmacy Market

NEXUS PHARMACEUTICALS RECEIVES FDA APPROVAL FOR 0.9% SODIUM CHLORIDE INJECTION

businesswire | August 31, 2023

news image

Nexus Pharmaceuticals LLC announced it has received U.S. Food and Drug Administration (FDA) approval for 0.9% Sodium Chloride Injection, USP in 10mL and 20mL Single-Dose Vials. “This product is part of an expanding portfolio of products that address critical healthcare challenges,” said Omair Ahmed, Chief Operating Officer. “Sodium Chloride Injection is used to treat patients every day in every hospital in the United States. We are grateful to be able to bolste...

Read More

PHARMACY MARKET

BIOMAP ESTABLISHES A STRATEGIC COLLABORATION WITH SANOFI TO CO-DEVELOP AI MODULES TO ACCELERATE DRUG DISCOVERY FOR BIOTHERAPEUTICS

Business Wire | October 17, 2023

news image

BioMap announced a groundbreaking strategic collaboration with Sanofi to co-develop cutting-edge AI modules for biotherapeutic drug discovery leveraging BioMap’s AI platform. “As the largest foundational model-based approach within life sciences, we are thrilled to collaborate with Sanofi and leverage the potential of BioMap’s cutting-edge AI engine to help solve compl...

Read More
news image

Business Insights, PHARMA TECH

CONTINUUS PHARMACEUTICALS ADOPTS DIGITAL VALIDATION

CONTINUUS Pharmaceuticals | March 15, 2023

On March 14, 2023, ValGenesis, Inc., a leading enterprise validation lifecycle management solutions provider, announced that CONTINUUS Pharmaceuticals has successfully implemented the ValGenesis Validation Lifecycle Management System (VLMS) for efficient management of validation processes across the company in a 100% digital format. CONTINUUS Pharmaceuticals is a rapidly growing small business specializing in end-to-end integrated continuous manufacturing (ICM) of pharmaceutical...

Read More
news image

Business Insights, PHARMACY MARKET

XERIS PHARMACEUTICALS ANNOUNCES USFDA APPROVAL OF RECORLEV

Xeris Pharmaceuticals, Inc. | January 31, 2023

On January 30, 2023, Xeris Biopharma Holdings, Inc., a leading biopharmaceutical company, announced that the Food and Drug Administration (FDA) granted orphan-drug exclusivity (ODE) to its subsidiary Xeris Pharmaceuticals, Inc. for Recorlev® (levoketoconazole) a cortisol synthesis inhibitor for the treatment of endogenous Cushing's syndrome in adult patients for whom surgery is not viable or has not been effective. levoketoconazole (Recorlev) being the first FDA-approved...

Read More
news image

Pharmacy Market

NEXUS PHARMACEUTICALS RECEIVES FDA APPROVAL FOR 0.9% SODIUM CHLORIDE INJECTION

businesswire | August 31, 2023

Nexus Pharmaceuticals LLC announced it has received U.S. Food and Drug Administration (FDA) approval for 0.9% Sodium Chloride Injection, USP in 10mL and 20mL Single-Dose Vials. “This product is part of an expanding portfolio of products that address critical healthcare challenges,” said Omair Ahmed, Chief Operating Officer. “Sodium Chloride Injection is used to treat patients every day in every hospital in the United States. We are grateful to be able to bolste...

Read More
news image

PHARMACY MARKET

BIOMAP ESTABLISHES A STRATEGIC COLLABORATION WITH SANOFI TO CO-DEVELOP AI MODULES TO ACCELERATE DRUG DISCOVERY FOR BIOTHERAPEUTICS

Business Wire | October 17, 2023

BioMap announced a groundbreaking strategic collaboration with Sanofi to co-develop cutting-edge AI modules for biotherapeutic drug discovery leveraging BioMap’s AI platform. “As the largest foundational model-based approach within life sciences, we are thrilled to collaborate with Sanofi and leverage the potential of BioMap’s cutting-edge AI engine to help solve compl...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us